Table 1.
Characteristics of the population at the time of kidney biopsy (KB)
| Clinical parameters | Patients (N = 100) | MD |
|---|---|---|
| Age (yr), median (IQR) | 47.0 (31.7–56.8) | 0 |
| BMI, median (IQR) | 20.0 (18.1–22.1) | 14 |
| Diabetes mellitus, n (%) | 51 (51.5) | 1 |
| Hypertension, n (%) | 60 (61.2) | 2 |
| Time between LT and KB (mo), median (IQR) | 26.3 (13.0–85.5) | 0 |
| Indication, n (%) | 0 | |
| Acute kidney injury | 20 (20) | |
| Chronic kidney disease | 72 (72) | |
| Isolated proteinuria | 4 (4) | |
| Assessment before lung re-transplantation | 4 (4) | |
| Time since sign of renal injurya(mo), median (IQR) | 15 (9–36) | 1 |
| Kidney function | ||
| eGFR (ml/min per 1.73 m2), median (IQR) | 32.5 (25–43) | 2 |
| Serum creatinine (μmol/l), median (IQR) | 185 (149–245) | 2 |
| Patient on hemodialysis, n (%) | 2 (2) | 0 |
| PCR (g/g), median (IQR) | 0.57 (0.24–2.1) | 3 |
| PCR >0.5 g/g, n (%) | 56 (57.7) | 3 |
| Hematuria, n (%) | 13 (14.8) | 12 |
| Systemic TMA, n (%) | 15 (15) | 0 |
| Immunosuppressive treatment | ||
| Maintenance treatment, n (%) | 0 | |
| Steroids | 91 (91) | |
| Tacrolimus | 93 (93) | |
| Cyclosporine | 5 (5) | |
| Mycophenolate | 67 (67) | |
| Azathioprine | 9 (9) | |
| Everolimus | 32 (32) | |
| Rapamune | 2 (2) | |
| Leflunomide | 4 (4) | |
| Tacrolimus trough level (ng/ml), median (IQR) | 7.15 (5.2–8.9) | 22 |
| Everolimus trough level (ng/ml), median (IQR) | 4.5 (4.0–7.3) | 10 |
| Combination CNI + mTORi at KB, n (%) | 32 (32) | 0 |
BMI, body mass index; CNI, calcineurin inhibitor; eGFR: estimated glomerular filtration rate by chronic kidney disease-epidemiology collaboration 2021; IQR, interquartile range; KB, kidney biopsy; LT, lung transplantation; MD, missing data; mTORi, mTOR inhibitor; PCR, urinary protein-to-creatinine ratio; TMA, thrombotic microangiopathy.
a
For chronic kidney disease and isolated proteinuria.